BDSI BioDelivery Sciences International Inc.

6.49
-0.21  -3%
Previous Close 6.7
Open 6.7
Price To Book 8.54
Market Cap 583,634,141
Shares 89,928,219
Volume 1,286,193
Short Ratio
Av. Daily Volume 1,291,312
Stock charts supplied by TradingView

NewsSee all news

  1. BioDelivery Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference

    RALEIGH, N.C., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  2. BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors

    RALEIGH, N.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  3. BioDelivery Sciences Reports Strong Third Quarter Results, Raises Full Year 2019 and Provides 2020 Net Sales Expectations

    BELBUCA® Net Sales Increased by 115% versus Prior Year to All-time High of $26.5 Million Raises Full Year 2019 Total Company Net Sales Expectations to $105 - $110 Million Provides Full Year 2020 BELBUCA Net Sales

  4. BioDelivery Sciences to Present at the 10th Annual Jefferies Global Healthcare Conference in London

    RALEIGH, N.C., Nov. 07, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  5. BioDelivery Sciences to Report Third Quarter 2019 Financial Results and Host Conference Call on November 12, 2019

    RALEIGH, N.C., Oct. 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced its

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data released December 13, 2016 - primary endpoints not met.
Clonidine gel
Painful diabetic neuropathy (PDN)
Approved June 6, 2014.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL
Opioid dependence
Approved October 26, 2015.
BEMA Buprenorphine
Pain

Latest News

  1. BioDelivery Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference

    RALEIGH, N.C., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  2. BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors

    RALEIGH, N.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  3. BioDelivery Sciences Reports Strong Third Quarter Results, Raises Full Year 2019 and Provides 2020 Net Sales Expectations

    BELBUCA® Net Sales Increased by 115% versus Prior Year to All-time High of $26.5 Million Raises Full Year 2019 Total Company Net Sales Expectations to $105 - $110 Million Provides Full Year 2020 BELBUCA Net Sales

  4. BioDelivery Sciences to Present at the 10th Annual Jefferies Global Healthcare Conference in London

    RALEIGH, N.C., Nov. 07, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  5. BioDelivery Sciences to Report Third Quarter 2019 Financial Results and Host Conference Call on November 12, 2019

    RALEIGH, N.C., Oct. 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced its

  6. Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

    Calidi Biotherapeutics, Inc. ("Calidi"), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George

  7. Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases

    Deep Clinical-Stage Pipeline Combined With World-Class Leadership TeamOrbiMed Advisors LLC to Lead a Concurrent Capital Raise 9 Meters Biopharma, Inc. Will Be the New Name of the Combined NASDAQ-Listed Public Company

  8. BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®

    Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred or Preferred Exclusive RALEIGH, N.C.,

  9. BioDelivery Sciences Announces Participation in Upcoming Investor Conferences

    RALEIGH, N.C., Sept. 17, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  10. BioDelivery Sciences Announces Upcoming Investor Conference Presentations

    RALEIGH, N.C., Aug. 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  11. BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management

    RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, today